Pathways for outpatient management of venous thromboembolism in a UK centre

被引:13
作者
Condliffe R. [1 ]
机构
[1] Pulmonary Vascular Disease Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
关键词
Deep vein thrombosis; Oral anticoagulant; Patient pathway; Pulmonary embolism; Venous thromboembolism;
D O I
10.1186/s12959-016-0120-2
中图分类号
学科分类号
摘要
It has become widely recognised that outpatient treatment may be suitable for many patients with venous thromboembolism. In addition, non-vitamin K antagonist oral anticoagulants that have been approved over the last few years have the potential to be an integral component of the outpatient care pathway, owing to their oral route of administration, lack of requirement for routine anticoagulation monitoring and simple dosing regimens. A robust pathway for outpatient care is also vital; one such pathway has been developed at Sheffield Teaching Hospitals in the UK. This paper describes the pathway and the arguments in its favour as an example of best practice and value offered to patients with venous thromboembolism. The pathway has two branches (one for deep vein thrombosis and one for pulmonary embolism), each with the same five-step process for outpatient treatment. Both begin from the point that the patient presents (in the Emergency Department, Thrombosis Clinic or general practitioner's office), followed by diagnosis, risk stratification, treatment choice and, finally, follow-up. The advantages of these pathways are that they offer clear, evidence-based guidance for the identification, diagnosis and treatment of patients who can safely be treated in the outpatient setting, and provide a detailed, stepwise process that can be easily adapted to suit the needs of other institutions. The approach is likely to result in both healthcare and economic benefits, including increased patient satisfaction and shorter hospital stays. © 2016 The Author(s).
引用
收藏
相关论文
共 36 条
  • [11] Wells P.S., Anderson D.R., Rodger M., Forgie M., Kearon C., Dreyer J., Et al., Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis, N Engl J Med, 349, pp. 1227-1235, (2003)
  • [12] Wells P.S., Owen C., Doucette S., Fergusson D., Tran H., Does this patient have deep vein thrombosis?, JAMA, 295, pp. 199-207, (2006)
  • [13] Pisters R., Lane D.A., Nieuwlaat R., Vos C.B., Crijns H.J., Lip G.Y.H., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, pp. 1093-1100, (2010)
  • [14] Ruiz-Gimenez N., Suarez C., Gonzalez R., Nieto J.A., Todoli J.A., Samperiz L., Et al., Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry, Thromb Haemost, 100, pp. 26-31, (2008)
  • [15] Weitz J.I., Anticoagulation therapy in 2015: where we are and where we are going, J Thromb Thrombolysis, 39, pp. 264-272, (2015)
  • [16] Pharma B.A.G., Xarelto® (rivaroxaban) Summary of Product Characteristics, (2016)
  • [17] Bristol-Myers Squibb, Pfizer. Eliquis® (apixaban) Summary of Product Characteristics, (2016)
  • [18] Pradaxa® (dabigatran etexilate) Summary of Product Characteristics, (2016)
  • [19] Lixiana® (edoxaban) Summary of Product Characteristics, (2016)
  • [20] Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., Et al., Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, pp. 799-808, (2013)